EIT Pharma, Inc. ("EIT Pharma" or the "Company"), a biotechnology company focused on developing therapies for infectious ...
Annual Activity Report 2025 highlights strong progress in strengthening regional innovation ecosystems, with supported ventures attracting €579 million in external investment in 2025 – a 147% increase ...
The phase 3 D-LIVR study is the largest clinical trial conducted to date in chronic hepatitis D and continues to generate new analyses to inform the program's path forward. Under the leadership of CEO ...
EIT Pharma is a biotechnology company focused on advancing therapies for infectious diseases with significant unmet medical needs. The company is developing a portfolio of programs to address serious ...
KIRKLAND, Wash., Aug. 31, 2026 /PRNewswire/ -- EIT Pharma, Inc. ("EIT Pharma" or the "Company"), a biotechnology company focused on developing therapies for infectious diseases, today announced the ...
US biotechnology EIT Pharma, which focused on advancing therapies for infectious diseases, today appointed Dr Jose Toerne as ...
Should you have feedback on this article, please complete the fields below. Please indicate if your feedback is in the form of a letter to the editor that you wish to have published. If so, please be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results